138 related articles for article (PubMed ID: 32419339)
1. Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy.
Nguyen HQ; Iskenderian A; Ehmann D; Jasper P; Zhang Z; Rong H; Welty D; Narayanan R
CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):342-352. PubMed ID: 32419339
[TBL] [Abstract][Full Text] [Related]
2. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.
Tsuchida K
Acta Myol; 2008 Jul; 27(1):14-8. PubMed ID: 19108572
[TBL] [Abstract][Full Text] [Related]
3. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease.
Pearsall RS; Davies MV; Cannell M; Li J; Widrick J; Mulivor AW; Wallner S; Troy ME; Spaits M; Liharska K; Sako D; Castonguay R; Keates S; Grinberg AV; Suragani RNVS; Kumar R
Sci Rep; 2019 Aug; 9(1):11392. PubMed ID: 31388039
[TBL] [Abstract][Full Text] [Related]
4. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
Amthor H; Hoogaars WM
Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
[TBL] [Abstract][Full Text] [Related]
5. Follistatin-288-Fc Fusion Protein Promotes Localized Growth of Skeletal Muscle.
Castonguay R; Lachey J; Wallner S; Strand J; Liharska K; Watanabe AE; Cannell M; Davies MV; Sako D; Troy ME; Krishnan L; Mulivor AW; Li H; Keates S; Alexander MJ; Pearsall RS; Kumar R
J Pharmacol Exp Ther; 2019 Mar; 368(3):435-445. PubMed ID: 30563942
[TBL] [Abstract][Full Text] [Related]
6. Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.
Iskenderian A; Liu N; Deng Q; Huang Y; Shen C; Palmieri K; Crooker R; Lundberg D; Kastrapeli N; Pescatore B; Romashko A; Dumas J; Comeau R; Norton A; Pan J; Rong H; Derakhchan K; Ehmann DE
Skelet Muscle; 2018 Oct; 8(1):34. PubMed ID: 30368252
[TBL] [Abstract][Full Text] [Related]
7. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.
Hulmi JJ; Hentilä J; DeRuisseau KC; Oliveira BM; Papaioannou KG; Autio R; Kujala UM; Ritvos O; Kainulainen H; Korkmaz A; Atalay M
Free Radic Biol Med; 2016 Oct; 99():308-322. PubMed ID: 27554968
[TBL] [Abstract][Full Text] [Related]
8. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
9. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
10. Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.
Previtali SC; Gidaro T; Díaz-Manera J; Zambon A; Carnesecchi S; Roux-Lombard P; Spitali P; Signorelli M; Szigyarto CA; Johansson C; Gray J; Labolle D; Porte Thomé F; Pitchforth J; Domingos J; Muntoni F
Pharmacol Res; 2020 Sep; 159():104999. PubMed ID: 32535224
[TBL] [Abstract][Full Text] [Related]
11. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
12. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
[TBL] [Abstract][Full Text] [Related]
13. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
14. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
[TBL] [Abstract][Full Text] [Related]
15. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy.
McDonald CM; Ramirez-Sanchez I; Oskarsson B; Joyce N; Aguilar C; Nicorici A; Dayan J; Goude E; Abresch RT; Villarreal F; Ceballos G; Perkins G; Dugar S; Schreiner G; Henricson EK
Muscle Nerve; 2021 Feb; 63(2):239-249. PubMed ID: 33125736
[TBL] [Abstract][Full Text] [Related]
17. Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application.
Shen C; Iskenderian A; Lundberg D; He T; Palmieri K; Crooker R; Deng Q; Traylor M; Gu S; Rong H; Ehmann D; Pescatore B; Strack-Logue B; Romashko A; Baviello G; Gill J; Zhang B; Meiyappan M; Pan C; Norton AW
J Pharmacol Exp Ther; 2018 Aug; 366(2):291-302. PubMed ID: 29752426
[TBL] [Abstract][Full Text] [Related]
18. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a follistatin-derived myostatin inhibitory peptide.
Saitoh M; Takayama K; Hitachi K; Taguchi A; Taniguchi A; Tsuchida K; Hayashi Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126892. PubMed ID: 31874826
[TBL] [Abstract][Full Text] [Related]
20. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
